Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone- releasing hormone, AN-207

Cancer

Volumn 85, Issue 12, 1999, Pages 2608-2615

  Kahán, Zsuzsanna ^a,b,c   Nagy, Attila ^a,b   Schally, Andrew V ^a,b   Halmos, Gábor ^a,b   Arencibia, José M ^a,b   Groot, Kate ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Breast carcinoma; Cytotoxic LH RH analog; MX 1 human breast carcinoma xenograft; Receptor targeted chemotherapy

Indexed keywords

2 PYRROLINODOXORUBICIN; CYTOTOXIC AGENT; DRUG VEHICLE; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; MANNITOL; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIORECEPTOR ASSAY; RECEPTOR AFFINITY; RECEPTOR BINDING; TUMOR XENOGRAFT;

EID: 0033564104     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990615)85:12<2608::AID-CNCR17>3.3.CO;2-8     Document Type: Article

References (28)

1. McPherson K, Steel CM, Dixon JM. Breast cancer: Epidemiology, risk factors and genetics. Br Med J 1994;309:1003-6.
2. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24(S10);1997;S10-3-10.
3. 6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989;3:137-47.
4. Emons G, Schally AV. The use of luteinizing hormone-releasing hormone agonists and antagonists in gynecological cancers. Human Reprod Update 1994;9:1364-79.
5. Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janáky T. Effects of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo. Anticancer Drugs 1992;3:109-16.
6. Szepeshazi K, Schally AV, Nagy A, Halmos G, Groot K. Targeted cytotoxic luteinizing hormone-releasing hormone (LH-RH) analogs inhibit growth of estrogen-independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. Anticancer Drugs 1997;8:974-87.
7. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist, Nature 1985;313: 231-3.
8. Eidne KA, Flanagan CA, Harris NS, Millar RP. Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metabol 1987;64:425-32.
9. Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, et al. Inhibition of growth of MCF-7-MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Res Treat 1992;21: 35-45.
10. Lamharzi N, Halmos G, Armatis P, Schally AV. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. Int J Oncol 1998;12:671-5.
11. Schally AV, Nagy A, Szepeshazi K, Pinski J, Halmos G, Armatis P, et al. LH-RH analogs with cytotoxic radicals. In Filicori M, Flamigni C, editors. Treatment with GnRH analogs: controversies and perspectives. Carnforth, United Kingdom: Parthenon Publishing, 1996:33-44.
12. Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovács M, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996;93:7269-73.
13. Jungwirth A, Schally AV, Nagy A, Pinski J, Groot K, Galvan G, et al. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol 1997;10:877-84.
14. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, et al. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 1997;89:1803-9.
15. Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, et al. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate 1999; 38:151-8.
16. Halmos G, Nagy A, Lamharzi N, Schally AV. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high-affinity to human breast cancers. Cancer Lett 1999;136: 129-136.
17. Nagy A, Armatis P, Schally AV. High-yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc Natl Acad Sci USA 1996;93:2464-9.
18. Szepeshazi K, Schally AV, Halmos G, Szöke B, Groot K, Nagy A. Effect of cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors. Breast Cancer Res Treat 1996;40:129-39.
19. Munson PJ, Rodbard D. Ligand: a versatile computerized approach for characterization of ligand binding systems. Anal Biochem 1980;107:220-39.
20. Milovanovic S, Radulovic S, Schally AV. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor. Breast Cancer Res Treat 1992;24:147-58.
21. Miyazaki M, Schally AV, Nagy A, Lamharzi N, Halmos G, Szepeshazi K, et al. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. Am J Obstet Gynecol 1999;180:1095-1103.
22. Danila DC, Schally AV, Nagy A, Alexander JM. Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1999;96: 669-73.
23. Szöke B, Horváth J, Halmos G, Rékási Z, Groot K, Nagy K, et al. LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro. Peptides 1994;15:359-66.
24. Ripamonti M, Pessoni G, Pesenti E, Pastori M, Frao M, Bargiotti A, et al. In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells. Br J Cancer 1992; 65:703-7.
25. Watanabe M, Komeshima N, Nakajima S, Tsuruo T. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant and murine tumor cells. Cancer Res 1988;48:6653-7.
26. Arcamone F, Animati F, Berettoni M, Bigioni M, Capranico G, Casazza AM, et al. Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy. J Natl Cancer Inst 1997;89:1217-23.
27. Munkarah A, Chuang L, Lotzova E, Cook K, Morris M, Wharton JT. Comparative studies of taxol and taxotere on tumor growth and lymphocyte functions. Gynecol Oncol 1994;55: 211-6.
28. Kovács M, Schally AV, Nagy A, Koppán M, Groot K. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1997;94:1420-5.